Immune responses of six-transmembrane epithelial antigen of the prostate 4 functions as a novel biomarker in gastric cancer

Pancreatic cancer (PC) remains one of the most challenging diseases, with a very poor 5-year overall survival of around 11.5%. Kirsten rat sarcoma virus (KRAS) mutation is seen in 90%-95% of PC patients and plays an important role in cancer cell proliferation, differentiation, metabolism, and surviv...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of clinical oncology Vol. 14; no. 8; pp. 297 - 310
Main Authors Fang, Ze-Xuan, Hou, Yan-Yu, Wu, Zheng, Wu, Bing-Xuan, Deng, Yu, Wu, Hua-Tao, Liu, Jing
Format Journal Article
LanguageEnglish
Published Baishideng Publishing Group Inc 24.08.2023
Subjects
Basic Study
Online AccessGet full text

Cover

More Information
Summary:Pancreatic cancer (PC) remains one of the most challenging diseases, with a very poor 5-year overall survival of around 11.5%. Kirsten rat sarcoma virus (KRAS) mutation is seen in 90%-95% of PC patients and plays an important role in cancer cell proliferation, differentiation, metabolism, and survival, making it an essential mutation for targeted therapy. Despite extensive efforts in studying this oncogene, there has been little success in finding a drug to target this pathway, labelling it for decades as “undruggable”. In this article we summarize some of the efforts made to target the KRAS pathway in PC, discuss the challenges, and shed light on promising clinical trials.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Supported by the National Natural Science Foundation of China, No. 82273457 and No. 81501539; Guangdong Basic and Applied Basic Research Foundation, No. 2023A1515012762 and No. 2021A1515012180; Special Grant for Key Area Programs of Guangdong Department of Education, No. 2021ZDZX2040; and Science and Technology Special Project of Guangdong Province, No. 210715216902829.
Corresponding author: Jing Liu, MD, PhD, Academic Research, Associate Professor, Research Scientist, Senior Scientist, Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Breast Cancer, Cancer Hospital of Shantou University Medical College, No. 22 Xinling Road, Shantou 515041, China. jliu12@stu.edu.cn
Author contributions: Liu J and Fang ZX designed the research study; Fang ZX performed the research; Fang ZX, Hou YY, Wu Z, Wu BX, Deng Y, and Wu HT analyzed the research and wrote the manuscript; Liu J revised the manuscript critically; and all authors have read and approved the final manuscript.
ISSN:2218-4333
2218-4333
DOI:10.5306/wjco.v14.i8.297